09/28/2023 5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2023 5:50 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2023 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/27/2023 5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/12/2023 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2023 5:26 AM | Sequeira Ramona (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:33 AM | Bitetti Teresa Marie (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
|
07/10/2023 5:35 AM | Takeda Pharmaceutical (Subject) Wozniewski Thomas Otto Claus (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:16 AM | Kim Julie So-Young (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:20 AM | Duprey Lauren Rusckowski (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:22 AM | Pignagnoli Agosti Marcello (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:24 AM | Lugogo Mwana Pietrina (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:06 AM | Ricci Gabriele (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:09 AM | Plump Andrew Stewart (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:12 AM | Greco Gerard M (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:14 AM | Platford Giles Richard (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/06/2023 5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/03/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023 5:35 AM | Takeda Pharmaceutical (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
06/28/2023 5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
06/23/2023 5:13 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/23/2023 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/09/2023 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/01/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:11 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:14 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/26/2023 6:08 AM | Calithera Biosciences, Inc. (Issuer) Takeda Pharmaceutical (Reporting) Takeda Ventures, Inc. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/26/2023 6:08 AM | Calithera Biosciences, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
05/17/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/15/2023 5:09 AM | Takeda Pharmaceutical (Filer)
| Form SD Specialized Disclosure Report | |
05/11/2023 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/11/2023 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/30/2023 5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/20/2023 5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/16/2023 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/01/2023 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/10/2023 5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
02/09/2023 5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/07/2023 1:10 PM | BlackRock Inc. (Filed by) Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/07/2023 5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/03/2023 4:06 PM | Day One Biopharmaceuticals, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13G/A | |
02/03/2023 10:50 AM | Ovid Therapeutics Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13G/A | |
02/03/2023 10:48 AM | Ovid Therapeutics Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13G/A | |
02/03/2023 5:19 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by) Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2023 5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/10/2023 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/05/2023 5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/21/2022 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/13/2022 6:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/08/2022 5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/01/2022 4:47 PM | HilleVax, Inc. (Issuer) Takeda Pharmaceutical (Reporting) Takeda Vaccines, Inc. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/30/2022 5:28 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/04/2022 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/27/2022 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/14/2022 6:36 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/04/2022 5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |